# 2026-23367: FDA Clears Vitamin Shots for Generics, Not a Miracle Cure

2026-23367, Determination That M.V.I. PEDIATRIC (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-11-17; PRIA reads it as touching household money (as of 2026-11-17).

- Canonical: https://policyrisk.com/federal-register/2026-23367
- As of: 2026-11-17
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-23367
- Title: Determination That M.V.I. PEDIATRIC (Multiple Vitamins for Injection) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 73759
- Published: 2026-11-17
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-11-17

## In one line

FDA Clears Vitamin Shots for Generics, Not a Miracle Cure

## Summary

The FDA has decided that M.V.I. PEDIATRIC vitamins for injection weren’t taken off the market because they’re unsafe or don’t work. This means drug companies can now apply to make generic versions of these vitamins, helping more kids get access to affordable options. If all rules are followed, these generics could hit the market soon, possibly saving money for families and healthcare providers.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) has determined that M.V.I. PEDIATRIC (ascorbic acid 80 milligrams (mg)/ vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride equivalent (EQ) 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial), for injection, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for ascorbic acid 80 mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001 mg/ vial; dexpanthenol 5 mg/vial; ergocalciferol 0.01 mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine hydrochloride 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine hydrochloride EQ 1.2 mg base/vial; vitamin A 0.7 mg/ vial; vitamin E 7 mg/vial, for injection, if all other legal and regulatory requirements are met.

## Effects PRIA read

- ANDA pathway opened for generics: benefit, medium. The FDA determined that M.V.I. PEDIATRIC for injection was not withdrawn for reasons of safety or effectiveness. Because of that determination, abbreviated new drug applications (ANDAs) that reference this listed drug may be approved if they meet all other legal and regulatory requirements. The lis…
- Potential cheaper pediatric vitamin options: benefit, medium. Because ANDAs referencing M.V.I. PEDIATRIC may now be approved, drug companies can apply to make generic versions of this pediatric multivitamin injection. If those generics meet requirements and reach the market, parents and healthcare providers could have lower-cost options and greater access to…

## Related documents

- [2026-23351](https://policyrisk.com/federal-register/2026-23351): Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition, 2026-11-17
- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25

## Sources
- [2026-23367 on federalregister.gov](https://www.federalregister.gov/documents/2026/11/17/2026-23367/determination-that-mvi-pediatric-multiple-vitamins-for-injection-was-not-withdrawn-from-sale-for)
- [2026-23367 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-11-17/pdf/2026-23367.pdf)

## Related
- [Previous: 2026-23366, Determination That M.V.I. ADULT (Multiple Vitamins for Injection) Was Not Withd…](https://policyrisk.com/federal-register/2026-23366)
- [Next: 2026-23368, Notice of Intent To Prepare an Environmental Impact Statement for the Proposed…](https://policyrisk.com/federal-register/2026-23368)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-23367 (as of 2026-11-17).
